Loading…
What To Do About High Cost Therapies
According to Barlow, around half of those approvals will be in the oncology market, around a third will be in the orphan drugs category, and about an eighth will be in what Barlow called the "quantum leap" category-drugs that will radically alter current treatment paradigms. The timing of...
Saved in:
Published in: | Managed Healthcare Executive 2018-12, Vol.28 (12), p.45-45 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | According to Barlow, around half of those approvals will be in the oncology market, around a third will be in the orphan drugs category, and about an eighth will be in what Barlow called the "quantum leap" category-drugs that will radically alter current treatment paradigms. The timing of payments is and will be a problem with these medications. Since most require only a one-time treatment, the cost of treatment is largely front loaded. Another key takeaway from those surveys is that different payers will require different models based on the payer's size and needs. [...]any new plans would need to be tailored to individual payers to some degree. |
---|---|
ISSN: | 1533-9300 2150-7120 |